Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2

Oncogene

Volumn 28, Issue 21, 2009, Pages 2173-2184

  Piao, C ^a   Jin, M ^a,b   Kim, H B ^a   Lee, S M ^a   Amatya, P N ^a   Hyun, J W ^c   Chang, I Y ^a   You, H J ^a  

^a Chosun University   (South Korea)

^b YANBIAN UNIVERSITY   (China)

^c Jeju National University School of Medicine   (South Korea)

Author keywords

ERK1 2; invasion; MEK2; P53R2; transformation

Indexed keywords

DEOXYRIBONUCLEOSIDE TRIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN P53; PROTEIN P53 SUBUNIT R2; RAS PROTEIN; RIBONUCLEOTIDE REDUCTASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL INVASION; CONTROLLED STUDY; CYTOCHEMISTRY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MITOGEN-ACTIVATED PROTEIN KINASE 1; PHOSPHORYLATION; PROTEIN BINDING; RIBONUCLEOTIDE REDUCTASES; RNA, SMALL INTERFERING;

MAMMALIA;

EID: 67349265769     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.84     Document Type: Article

References (37)

1. Barnes DE, Lindahl T. (2004). Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet 38: 445-476.
2. Cao MY, Lee Y, FengNP, XiongK, Jin H, WangM et al. (2003). Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin Cancer Res 9: 4553-4561.
3. Chabes AL, Pfleger CM, Kirschner MW, Thelander L. (2003). Mouse ribonucleotide reductase R2 protein: a new target for anaphasepromotingcomplex- Cdh1-mediated proteolysis. Proc Natl Acad Sci USA 100: 3925-3929.
4. Chen M, Rahman L, Voeller D, Kastanos E, YangSX, Feigenbaum L et al. (2007). Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas. Oncogene 26: 4817-4824.
5. Devlin HL, Mack PC, Burich RA, Gumerlock PH, KungHJ, Mudryj M et al. (2008). Impairment of the DNA repair and growth arrest pathways by p53R2 silencingenhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells. Mol Cancer Res 6: 808-818.
6. Dhillon AS, Hagan S, Rath O, Kolch W. (2007). MAP kinase signalling pathways in cancer. Oncogene 26: 3279-3290.
7. Droge W. (2002). Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95.
8. Enslen H, Davis RJ. (2001). Regulation of MAP kinases by docking domains. Biol Cell 93: 5-14.
9. Fan H, Huang A, Villegas C, Wright JA. (1997). The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci USA 94: 13181-13186.
10. Fan H, Villegas C, Huang A, Wright JA. (1998). The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res 58: 1650-1653.
11. Fan H, Villegas C, Wright JA. (1996). Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci USA 93: 14036-14040.
12. Gautam A, Bepler G. (2006). Suppression of lungtumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res 66: 6497-6502.
13. Gautam A, Li ZR, Bepler G. (2003). RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene 22: 2135-2142.
14. Hakansson P, Hofer A, Thelander L. (2006). Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J Biol Chem 281: 7834-7841.
15. Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H. (2003). Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet 34: 440-445.
16. Kolch W. (2000). Meaningful relationships: the regulation of the Ras/ Raf/MEK/ERK pathway by protein interactions. Biochem J 351(Pt 2): 289-305.
17. Liu X, Zhou B, Xue L, Shih J, Tye K, Lin W et al. (2006). Metastasis-suppressingpotential of ribonucleotide reductase small subunit p53R2 in human cancer cells. Clin Cancer Res 12: 6337-6344.
18. Liu X, Zhou B, Xue L, Yen F, Chu P, Un F et al. (2007). Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin Colorectal Cancer 6: 374-381.
19. Mathews CK. (2006). DNA precursor metabolism and genomic stability. FASEB J 20: 1300-1314.
20. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, WongEW, ChangF et al. (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284.
21. Nakano K, Balint E, Ashcroft M, Vousden KH. (2000). A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 19: 4283-4289.
22. Nordlund P, Reichard P. (2006). Ribonucleotide reductases. Annu Rev Biochem 75: 681-706.
23. Powell DR, Desai U, Sparks MJ, Hansen G, Gay J, Schrick J et al. (2005). Rapid development of glomerular injury and renal failure in mice lackingp53R2. Pediatr Nephrol 20: 432-440.
24. Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegra C, Barrett JC et al. (2004). Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 5: 341-351.
25. Reddy KB, Nabha SM, Atanaskova N. (2003). Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22: 395-403.
26. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K et al. (2000). A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404: 42-49.
27. Tsai MH, Chen X, Chandramouli GV, Chen Y, Yan H, Zhao S et al. (2006). Transcriptional responses to ionizingradiation reveal that p53R2 protects against radiation-induced mutagenesis in human lymphoblastoid cells. Oncogene 25: 622-632.
28. Widmann C, Gibson S, Jarpe MB, Johnson GL. (1999). Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79: 143-180.
29. Xu X, Page JL, Surtees JA, Liu H, Lagedrost S, Lu Y et al. (2008). Broad overexpression of ribonucleotide reductase genes in mice specifically induces lungneoplasms. Cancer Res 68: 2652-2660.
30. Xue L, Zhou B, Liu X, HeungY, Chau J, Chu E et al. (2007). Ribonucleotide reductase small subunit p53R2 facilitates p21 induction of G1 arrest under UV irradiation. Cancer Res 67: 16-21.
31. Xue L, Zhou B, Liu X, Qiu W, Jin Z, Yen Y. (2003). Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res 63: 980-986.
32. Xue L, Zhou B, Liu X, WangT, Shih J, Qi C et al. (2006). Structurally dependent redox property of ribonucleotide reductase subunit p53R2. Cancer Res 66: 1900-1905.
33. Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujino MA, Nakamura Y et al. (2001). p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res 61: 8256-8262.
34. Yoon S, Seger R. (2006). The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24: 21-44.
35. Yoshida T, Haga S, Numata Y, Yamashita K, Mikami T, Ogawa T et al. (2006). Disruption of the p53-p53r2 DNA repair system in ulcerative colitis contributes to colon tumorigenesis. Int J Cancer 118: 1395-1403.
36. ZhengZ, Chen T, Li X, Haura E, Sharma A, Bepler G. (2007). DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356: 800-808.
37. Zhou BS, Tsai P, Ker R, Tsai J, Ho R, Yu J et al. (1998). Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 16: 43-49.